Abstract:Despite improvements in clinical outcomes following acute myocardial infarction, mortality remains high, especially in patients with severely reduced left ventricular ejection fraction (LVEF <30%), emphasizing the need for effective cardioprotective strategies adjunctive to recanalization. Traditional cell therapy has shown equivocal success, shifting the focus to innovative cardioactive biologicals and cell mimetic therapies, particularly extracellular vesicles (EVs). EVs, as carriers of non-coding RNAs and other essential biomolecules, influence neighbouring and remote cell function in a paracrine manner. Compared to cell therapy, EVs possess several clinically advantageous traits, including stability, ease of storage (enabling off-the-shelf clinical readiness), and decreased immunogenicity. Allogeneic EVs from mesenchymal and/or cardiac stromal progenitor cells demonstrate safety and potential efficacy in preclinical settings. This review delves into the translational potential of EV-based therapeutic approaches, specifically highlighting findings from large-animal studies, and offers a synopsis of ongoing early-stage clinical trials in this domain. Inflammation plays a significant role in acute myocardial infarction, affecting both the early phase following the clinical presentation of acute coronary syndrome and the subsequent chronic phase. During the acute phase, various inflammatory cell types, such as T-cells, granulocytes, monocytes, and B-cells, are attracted to the infarcted area to remove necrotic tissue and promote scar tissue formation. Initially, pro-inflammatory cells like polymorphonuclear neutrophils and M1 pro-inflammatory macrophages are predominant. Within 24–48 h, these M1 macrophages transition into an anti-inflammatory M2 state, contributing to the healing process. T-cells, including CD8+ and CD4+ types, are activated within lymph nodes connected to the heart and play a role in the healing process. Experiments conducted in small and large animals suggest a potential therapeutic role for exogenous extracellular vesicles (EVs) as an adjunctive therapy to percutaneous coronary intervention. EV-mediated modulation of the immune response facilitates a transition from an inflammatory state to a resolving phase after ischaemic damage. Abbreviations: DAMPS, damage-associated molecular pattern molecules; GM-CSF, granulocyte-macrophage colony stimulating factor; IL, Interleukin; IL-1ra, interleukin-1 receptor antagonist; Ly-6C, lymphocyte antigen; M1, inflammatory monocytes/macrophages; M2, reparative monocytes/macrophages; TGFB, transforming growth factor beta; Th2, T-helper cells; TNF-α, tumour necrosis factor alpha.

Micronized Acellular Matrix Biomaterial Leverages Eosinophils for Postinfarct Cardiac Repair

Extracellular Matrix/Glycopeptide Hybrid Hydrogel as an Immunomodulatory Niche for Endogenous Cardiac Repair after Myocardial Infarction

Cathepsin S-mediated Fibroblast Trans-Differentiation Contributes to Left Ventricular Remodelling after Myocardial Infarction.

Pericardial Delivery of Sodium Alginate-Infusible Extracellular Matrix Composite Hydrogel Promotes Angiogenesis and Intercellular Electrical Conduction after Myocardial Infarction

Acellular bioscaffolds redirect cardiac fibroblasts and promote functional tissue repair in rodents and humans with myocardial injury

Cardiac-Restricted IGF-1Ea Overexpression Reduces the Early Accumulation of Inflammatory Myeloid Cells and Mediates Expression of Extracellular Matrix Remodelling Genes after Myocardial Infarction

Myocardial matrix hydrogel acts as a reactive oxygen species scavenger and supports a proliferative microenvironment for cardiomyocytes

In situ constructive myocardial remodeling of extracellular matrix patch enhanced with controlled growth factor release

Elastomeric cardiopatch scaffold for myocardial repair and ventricular support

Extracellular matrix remodeling following myocardial infarction influences the therapeutic potential of mesenchymal stem cells

Injury minimization after myocardial infarction: focus on extracellular vesicles

Eosinophils improve cardiac function after myocardial infarction

Biomaterials Loaded with Growth Factors/Cytokines and Stem Cells for Cardiac Tissue Regeneration

Extracellular Matrix Protein-1 as a Mediator of Inflammation-Induced Fibrosis After Myocardial Infarction

Abstract 11466: CBSCs Derived Extracellular Vesicles Modify the Immune Response After Cardiac Ischemic Injury to Enhance Repair

Restoring Cardiac Functions after Myocardial Infarction–Ischemia/Reperfusion via an Exosome Anchoring Conductive Hydrogel

Brown Adipose Stem Cell-Loaded Resilin Elastic Hydrogel Rebuilds Cardiac Function after Myocardial Infarction via Collagen I/III Reorganisation

Abstract 16837: Exosomes Derived From Podoplanin Positive Cells Induce Serum Amyloid A3 Amyloidosis in Healthy Mouse Heart

Intervening to preserve function in ischemic cardiomyopathy with a porous hydrogel and extracellular matrix composite in a rat myocardial infarction model

miR-182/183-Rasa1 axis induced macrophage polarization and redox regulation promotes repair after ischemic cardiac injury

Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction